about
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literatureElevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.The role of Dickkopf-3 overexpression in esophageal adenocarcinomaEpigenetic regulation of vitamin D metabolism in human lung adenocarcinoma.A Novel Serum 4-microRNA Signature for Lung Cancer Detection.A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancerCombined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer RiskIntrinsic cancer subtypes-next steps into personalized medicineFasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapyPhase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancerParaneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancerIncidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancerPreoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancerMET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung CancerComment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiationRamucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialInhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 NetworkEpigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysisImmunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivorsThyroid dysfunction induced by nivolumab: searching for disease patterns and outcomesMultidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastasesStarvation and antimetabolic therapy promote cytokine release and recruitment of immune cellsSafety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trialMulticenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer
P50
Q26851579-5E7CD011-92A5-4E2B-8501-31C220B629CBQ30316699-594EA555-E022-4A04-B10C-32DF6241DA9EQ34165233-4A1255D2-341B-4864-8761-641D15AEC396Q34762165-6E073937-1405-4BC6-9A26-793582042757Q35889299-4C3400EE-83A1-43E9-8BEA-D2A5E2D77379Q37714772-660FFD75-8E1B-4CD3-80E7-D162F359E49AQ37736206-9A9B5450-B330-4CF6-9FB6-2DB5895A08D5Q38599094-6E574C81-E039-4321-AD8F-A292D386F302Q38795629-B7C766B6-021F-437F-AC3F-D24FE12F688EQ38956964-AE87C62A-6CB0-4359-8ABA-5ED559DF6FDEQ38961825-2DE7B6FA-4295-4611-8372-9329E7E77DE7Q39843151-F6DB41CC-29A4-42F0-AF3E-925B0BF53F3CQ42366634-951226CB-4BA2-4BD4-BF91-A6038E2DEBB2Q43167252-069C1B19-F4DB-4C1F-8EC5-979C1A09EDBEQ46463395-267F9016-592E-482C-8466-EE652465BB1EQ47400935-A326A521-A361-426C-B4B0-4EB27FFA0EBFQ47643885-D4CA20E6-41DF-4BF4-82C0-F06801F029CBQ48091386-F4DFDC7D-C954-437F-A393-7945D6D402ADQ49887897-C6DB8D48-49C5-4266-888C-0D6946225327Q50114297-DC7EAF6D-005A-41A9-ADDD-14D04A4D1F6DQ52587593-9A7983D9-7AB9-4C5F-BB9F-367D0CD0A05EQ54977899-38BF271A-62EF-484D-9F84-47589B42151FQ57239831-3E2BE2BB-B34E-42AD-B4F2-89DFC97230A1Q58053534-081506B4-C32D-4322-9198-1F0591FB2B18Q64117465-A288C0AE-9111-4E8F-B2AD-19A8ABEC5E2CQ83480323-72729A0D-A613-47E0-955A-5D236F0F4F3FQ84218860-94178242-F354-4621-AD9C-2A1302D41C42Q88123740-E6253D45-4134-4D72-B30F-9B31D33CB10CQ88445879-BF799CD7-7849-4D93-8634-4F95822900CFQ89093365-B0EE2D87-DBEB-42D3-A066-D400E0D047E8Q90428444-63621E14-0C45-40F0-BFEA-6A16EE87B700Q90572119-EF57E96D-94FA-439C-9E1F-5EC500BE9FE6Q90622284-904ABFB0-1C46-482F-AB8A-5867FB813EF8Q90904632-029ED6C7-E869-400B-95E3-4E73C003CE5CQ91374100-0B9C7EC9-0D11-46F0-ABCF-CC3BEC61E128Q91918364-8EB46276-3AAA-4DB9-A1A8-9D121BBBA967Q92048201-28561367-3EFA-4881-B6E5-B444850A8BD6Q92091506-A160F1D3-2864-4302-846F-4EFEA5DB80D0Q92757996-C2BE9B24-B183-4AD6-9079-2C71D771FDE3Q92839958-CEED92DD-54E4-4855-8E2E-4C6DF62A1AE6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ernest Nadal
@ast
Ernest Nadal
@en
Ernest Nadal
@es
Ernest Nadal
@nl
Ernest Nadal
@sl
type
label
Ernest Nadal
@ast
Ernest Nadal
@en
Ernest Nadal
@es
Ernest Nadal
@nl
Ernest Nadal
@sl
prefLabel
Ernest Nadal
@ast
Ernest Nadal
@en
Ernest Nadal
@es
Ernest Nadal
@nl
Ernest Nadal
@sl
P108
P106
P1153
36619073100
P21
P31
P496
0000-0002-9674-5554